Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Iovance Biotherapeutics call volume above normal and directionally bullish » 14:05
03/30/20
03/30
14:05
03/30/20
14:05
IOVA

Iovance Biotherapeutics

$27.93 /

-4.21 (-13.10%)

Bullish option flow…

Bullish option flow detected in Iovance Biotherapeutics with 4,730 calls trading, 1.1x expected, and implied vol increasing over 1 point to 146.32%. Apr-20 30 calls and Apr-20 40 calls are the most active options, with total volume in those strikes near 3,500 contracts. The Put/Call Ratio is 0.04. Earnings are expected on May 7th.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Iovance Biotherapeutics call volume above normal and directionally bullish » 14:05
03/24/20
03/24
14:05
03/24/20
14:05
IOVA

Iovance Biotherapeutics

$28.56 /

+4.69 (+19.65%)

Bullish option flow…

Bullish option flow detected in Iovance Biotherapeutics with 7,069 calls trading, 1.3x expected, and implied vol increasing over 18 points to 155.76%. Apr-20 40 calls and Jun-20 30 calls are the most active options, with total volume in those strikes near 4,400 contracts. The Put/Call Ratio is 0.03. Earnings are expected on May 7th.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Iovance jumps as cancelled conference call renews buyout speculation » 13:50
03/24/20
03/24
13:50
03/24/20
13:50
IOVA

Iovance Biotherapeutics

$28.64 /

+4.77 (+19.98%)

Shares of Iovance…

Shares of Iovance Biotherapeutics moved higher after Jefferies analyst Biren Amin noted that the firm's conference call with management scheduled for March 25 was cancelled by the company. Bloomberg on February 25 reported that Iovance is exploring a sale and has held preliminary talks with potential buyers. Iovance is working with a financial adviser after receiving takeover interest, a source told Bloomberg. Investors seem to be speculating that Iovance's cancelled call may portend to a takeover. The stock in afternoon trading is up 21%, or $5.03, to $28.84.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Iovance Biotherapeutics conference call canceled, says Jefferies » 13:26
03/24/20
03/24
13:26
03/24/20
13:26
IOVA

Iovance Biotherapeutics

$25.83 /

+1.96 (+8.21%)

Jefferies analyst Biren…

Jefferies analyst Biren Amin noted that the firm's conference call scheduled for March 25 with Iovance Biotherapeutics was cancelled by the company. Following notice of the conference cancellation, Iovance shares are up $5.97, or 25%, to $29.77.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Clinigen Group upgraded to Buy from Hold at Liberum » 04:46
03/11/20
03/11
04:46
03/11/20
04:46
CLIGF

Clinigen Group

$0.00 /

+ (+0.00%)

, IOVA

Iovance Biotherapeutics

$31.98 /

-0.045 (-0.14%)

Liberum analyst Graham…

Liberum analyst Graham Doyle upgraded Clinigen Group (CLIGF) to Buy from Hold with a 780 GBp price target. The shares do not attribute any value to partner Iovance's (IOVA) cancer therapy trials, which also use Clinigen's Proleukin, Doyle tells investors in a research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Initiation
Barclays starts small, mid cap Biotechnology sector with Positive view » 09:15
03/04/20
03/04
09:15
03/04/20
09:15
IOVA

Iovance Biotherapeutics

$35.76 /

-0.2 (-0.56%)

, EXEL

Exelixis

$18.72 /

-0.57 (-2.95%)

, RCUS

Arcus Biosciences

$16.65 /

-0.85 (-4.86%)

, NKTR

Nektar

$19.46 /

-0.67 (-3.33%)

, EPZM

Epizyme

$20.71 /

-2.33 (-10.11%)

, FATE

Fate Therapeutics

$28.31 /

-2.78 (-8.94%)

, DCPH

Deciphera

$55.98 /

-1.06 (-1.86%)

, CTMX

CytomX Therapeutics

$7.28 /

+0.18 (+2.54%)

, MGNX

MacroGenics

$8.63 /

-0.27 (-3.03%)

, XNCR

Xencor

$32.59 /

+0.31 (+0.96%)

Barclays analyst Peter…

Barclays analyst Peter Lawson initiated coverage of 13 companies in the U.S. small and mid cap Biotechnology sector with a Positive view. His coverage includes nine Overweights, two Equal Weights, and two Underweights. Small and mid cap biotech stocks should outperform on positive pivotal data, commercialization of novel therapies, and early clinical data from potential disruptive therapies, Lawson tells investors in a research note. He believes the four stocks with the most potential upside, based on probability-adjusted outcomes of upcoming catalysts, are Exelixis (EXEL), Arcus Biosciences (RCUS), Nektar Therapeutics (NKTR) and Epizyme (EPZM). Lawson also recommends investors focus on differentiated therapies from Iovance (IOVA) and Fate Therapeutics (FATE). He also believes Deciphera's (DCPH) first commercial product positions the company well in gastrointestinal stromal tumors. Lawson is awaiting further data to be more constructive on Equal Weight-rated CytomX Therapeutics (CTMX) and Underweight-rated MacroGenics (MGNX) and Xencor (XNCR).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Iovance Biotherapeutics initiated with an Overweight at Barclays » 05:04
03/04/20
03/04
05:04
03/04/20
05:04
IOVA

Iovance Biotherapeutics

$35.76 /

-0.2 (-0.56%)

Barclays analyst Peter…

Barclays analyst Peter Lawson initiated coverage of Iovance Biotherapeutics with an Overweight rating and $45 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Iovance Biotherapeutics price target raised to $36 from $32 at H.C. Wainwright » 07:14
02/26/20
02/26
07:14
02/26/20
07:14
IOVA

Iovance Biotherapeutics

$31.61 /

+6.92 (+28.03%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis raised the firm's price target on Iovance Biotherapeutics to $36 from $32 and keeps a Buy rating on the shares. The company's primary focus for 2020 remains both delivering pivotal data for melanoma and cervical cancer, and filing both Biologics License Applications by year-end, Pantginis tells investors in a post-earnings research note. The analyst also highlights the potential for a takeout of Iovance, which he says has been an underlying thesis of his for years and resurfaced in unconfirmed press reports again yesterday.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Iovance Biotherapeutics price target raised to $38 from $32 at Wells Fargo » 06:39
02/26/20
02/26
06:39
02/26/20
06:39
IOVA

Iovance Biotherapeutics

$31.61 /

+6.92 (+28.03%)

Wells Fargo analyst Jim…

Wells Fargo analyst Jim Birchenough raised the firm's price target on Iovance Biotherapeutics to $38 from $32 and reiterates an Overweight rating on the shares. The new price target is based on a sum-of-the-parts reflecting increased likelihood of success for the company's tumor infiltrating lymphocytes pipeline for melanoma and cervical cancer, Birchenough tells investors in a research note. The analyst sees "multiple opportunities for sustainable value creation" following Iovance's Q4 results. Birchenough says that with earlier payer engagement, broader site experience and improving reimbursement landscape for early CAR-T launches, he sees potential for more rapid adoption, in larger solid tumor indications and with greater commercial opportunity.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Iovance Biotherapeutics price target raised to $40 from $30 at Piper Sandler » 21:02
02/25/20
02/25
21:02
02/25/20
21:02
IOVA

Iovance Biotherapeutics

$31.61 /

+6.92 (+28.03%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro raised his price target on Iovance Biotherapeutics to $40 and kept his Outperform rating after its Q4 earnings beat and with the company announcing that its timelines for melanoma and cervical registrational cohort filings remaining unchanged by year-end FY20. The analyst also maintains his view of Iovance as the leader in solid tumor targeting cell therapy and contends that some of its rumored potential acquirers do as well.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.